196 related articles for article (PubMed ID: 22316209)
1. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.
Gameiro SR; Caballero JA; Hodge JW
Cancer Biother Radiopharm; 2012 Feb; 27(1):23-35. PubMed ID: 22316209
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
Gameiro SR; Caballero JA; Higgins JP; Apelian D; Hodge JW
Cancer Immunol Immunother; 2011 Sep; 60(9):1227-42. PubMed ID: 21544650
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Gelbard A; Garnett CT; Abrams SI; Patel V; Gutkind JS; Palena C; Tsang KY; Schlom J; Hodge JW
Clin Cancer Res; 2006 Mar; 12(6):1897-905. PubMed ID: 16551875
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Hodge JW; Garnett CT; Farsaci B; Palena C; Tsang KY; Ferrone S; Gameiro SR
Int J Cancer; 2013 Aug; 133(3):624-36. PubMed ID: 23364915
[TBL] [Abstract][Full Text] [Related]
7. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Gavrilov V; Lavrenkov K; Ariad S; Shany S
Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
[TBL] [Abstract][Full Text] [Related]
8. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
9. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
Hiraki A; Ono T; Tanaka M; Kiura K; Ueoka H; Kawai H; Harada M; Nakayama E; Noguchi Y
Anticancer Res; 2001; 21(4A):2561-7. PubMed ID: 11724322
[TBL] [Abstract][Full Text] [Related]
10. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
11. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
12. Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer.
Quantin X; Khial F; Reme-Saumon M; Michel FB; Pujol JL
Lung Cancer; 1999 Oct; 26(1):35-9. PubMed ID: 10574679
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
Winton T; Livingston R; Johnson D; Rigas J; Johnston M; Butts C; Cormier Y; Goss G; Inculet R; Vallieres E; Fry W; Bethune D; Ayoub J; Ding K; Seymour L; Graham B; Tsao MS; Gandara D; Kesler K; Demmy T; Shepherd F; ;
N Engl J Med; 2005 Jun; 352(25):2589-97. PubMed ID: 15972865
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.
Merritt RE; Mahtabifard A; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1609-17. PubMed ID: 14666041
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
18. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
19. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
